(Q40064054)

English

Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

scientific article published on 30 July 2008

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

0 references

0 references

Alzheimer's disease

0 references

9

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Henrik Zetterberg

3

object named as

Henrik Zetterberg

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

2

object named as

Kaj Blennow

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Colin L. Masters

7

object named as

Colin L Masters

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Craig W Ritchie

12

object named as

Craig W Ritchie

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

1

object named as

Lars Lannfelt

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

author name string

Stellan Batsman

4

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

David Ames

5

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

John Harrison

6

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Steve Targum

8

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Ross Murdoch

10

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Janet Wilson

11

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

PBT2-201-EURO study group

13

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

30 July 2008

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Lancet Neurology

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

779-786

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970167-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970167-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A beta oligomers - a decade of discovery

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970167-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970167-4

7 January 2021

based on heuristic

inferred from DOI database lookup

NMDA receptor activation mediates copper homeostasis in hippocampal neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970167-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid induction of Alzheimer A beta amyloid formation by zinc.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970167-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970167-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970167-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970167-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970167-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970167-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Disease-modifying therapies for Alzheimer disease: challenges to early intervention

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970167-4

7 January 2021

based on heuristic

inferred from DOI database lookup

“Mini-mental state”

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970167-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A new rating scale for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970167-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970167-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Metal-protein attenuating compounds and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970167-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970167-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970167-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970167-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A neuropsychological test battery for use in Alzheimer disease clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970167-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970167-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Longitudinal stability of CSF biomarkers in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970167-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970167-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Disease-modifying therapies in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970167-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(08)70167-4

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40064054&oldid=1883449912"